Las Vegas hospital Nevada's first with 2 cutting-edge treatments
CAR T-cell therapy involves turning a patient's own cells into powerful weapons against their disease, while allogeneic stem cell transplant uses healthy donor cells to aid in recovery. These highly complex and sophisticated therapies have become a crucial tool in extending and, in many cases, saving the lives of patients with hard-to-treat disorders.
'There are two therapies. One is allogeneic stem cell transplant, which allows us to provide stem cells from other donors to patients who have a need for that. We are also bringing CAR T therapy which uses the patient's own cells,' said Dr. Carolyn Mulroney, medical director of the Sarah Cannon transplant and the CAR T-cell therapy program.
Usually, many patients and their families have been forced to travel out of state to access these advanced treatments, adding financial stress and uncertainty during a difficult time. Now, thanks to MountainView's Sarah Cannon Transplant & Cellular Therapy Program, these lifesaving options are available close to home, supported by a team of multidisciplinary experts.
This significant breakthrough comes just ahead of the grand opening for MountainView's first-of-its-kind 12,000-square-foot Day Hospital, a state-of-the-art facility designed to provide convenient, patient-centric care under one roof.
The new Day Hospital will enable patients to undergo extensive treatments while retaining their routines and staying connected with their support networks.
'In an outpatient setting like this, it allows the patient to go home at the end of the day, sleep in their own bed, and be with their family,' Maria Rios, administrative director at MountainView Hospital, said.
This marks a major step forward in health care for Nevada, ensuring that patients battling some of the most aggressive blood disorders can find hope without having to leave their community.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
15 hours ago
- USA Today
Wegmans chocolate sold in 8 states recalled over undeclared allergen
A Wegmans chocolate product was recently recalled due to the presence of an undeclared allergen. Mellace Family Brands California, Inc. of Warren, Ohio initiated the recall, informing the Food and Drug Administration on June 25 that Wegmans Semi-Sweet Chocolate Nonpareils, chocolate-flavored balls made of sugar and starch, contained milk. "The recall was initiated after it was discovered that Wegmans Semi-Sweet Chocolate Nonpareils contained a milk allergen and was distributed in packaging that did not reveal the presence of milk," the FDA notice says. "(A) subsequent investigation indicates the problem was caused by a temporary breakdown in the suppliers' manufacturing process." Anyone with an allergy or severe sensitivity to milk run the risk of a serious or life-threatening allergic reaction if they consume the recalled product, according to the FDA notice. The candy was distributed through Wegmans stores in eight states, including Delaware, Maryland, Massachusetts, North Carolina, New Jersey, New York, Pennsylvania, Virginia and Washington D.C. There have been no confirmed reports of injuries or illness due to the consumption of the chocolate-flavored decorative confections. Here's what to know about the Wegmans chocolate recall. Need a break? Play the USA TODAY Daily Crossword Puzzle Wegmans chocolate recall: Affected products Consumers who have purchased the Wegmans Semi-Sweet Chocolate Nonpareils with specific lot codes are urged to return the product to the place of purchase for a full refund. According to the FDA notice, the product is packaged in a plastic tub labeled Wegmans Semi-Sweet Chocolate Nonpareils 18.5oz (1LB 2.5OZ) 524g, UPC 0 77890 49787 6, SCC 10077890497873. The product's lot code and best by date can be found on the left side of the tub. Affected lot codes include: Consumers with any questions, or concerns about the recalled product may contact Wegmans Food Markets by phone at (855)-934-3663 from 8 a.m. through 8 p.m. ET daily.
Yahoo
17 hours ago
- Yahoo
American Healthcare REIT Announces Dates for Second Quarter 2025 Earnings Release and Conference Call
IRVINE, Calif., July 1, 2025 /PRNewswire/ -- American Healthcare REIT, Inc. (the "Company") (NYSE: AHR) announced today that it will issue its second quarter 2025 earnings release on Thursday, August 7, 2025, after the close of trading. A public conference call with a simultaneous webcast will be held on Friday, August 8, 2025, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. During the conference call, company executives will review second quarter 2025 results, discuss recent events, and conduct a question-and-answer period. To join via webcast, investors may use the following link: To join the live telephone conference call, please dial one of the following numbers at least five minutes prior to the start time: North America Toll-Free: (800) 715-9871International Toll: +1 (646) 307-1963Conference ID: 2930459 A digital replay of the call will be available in the Investor Relations section of the Company's website at shortly after the conclusion of the call. The full text of the earnings report and supplemental data will be available immediately following the earnings release to the wire services on August 7, 2025, in the Investor Relations section of the Company's website at About American Healthcare REIT, Inc. American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing communities, skilled nursing, and outpatient medical buildings across the United States, and in the United Kingdom and the Isle of Man. Investor Contact: Alan PetersonVP, Investor Relations & Finance(949) 270-9200investorrelations@ Media Contact:Damon ElderSpotlight Marketing Communications(949) 427-1377damon@ View original content to download multimedia: SOURCE American Healthcare REIT, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18 hours ago
- Business Wire
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at in the 'Events & Presentations' section. To access the call by phone, please use this link ( and you will be provided with dial-in details, including a personal pin. An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care's Investor Center website located at in the 'Events & Presentations' section. About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.
